Buying Ecstasy Mannheim

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Buying Ecstasy Mannheim

On July 13, there was a rainy sky above the southern German city of Mannheim. But, despite the uninspiring weather, it was a day of hope for millions of people with depression — because the first patients of a research project run by the Central Institute of Mental Health were scheduled to have a psychedelic experience. They wore a blindfolds and headphones that played music and were accompanied by two therapists. The hallucinogen used for the inner journey is called psilocybin. This active ingredient was isolated about 60 years ago. It gives the magic mushrooms their 'magic' — i. And it has been banned almost worldwide, including in Germany, for over half a century. Even for the Mannheim researchers, 'obtaining the substance has proven to be the highest hurdle. It was a long and laborious process,' he said. But that laborious process is becoming more common. Hallucinogenic trips have long ceased to be solely the recreational pastime of hippies. A growing number of scientific studies point to the potential of psilocybin-assisted therapy for treating depressed patients — even those for whom other therapies have been exhausted. According to estimates by the World Health Organization, about million people worldwide live with depression. In Germany, that number is an estimated 5 million, and the Health Ministry has referred to it as a 'widespread disease. A conservative estimate is that around one in five patients cannot be helped with conventional treatment methods. In conventional therapies, patients are treated with daily doses of antidepressants. The new approach is fundamentally different. Subjects in earlier studies reported life-changing experiences and significantly improved mental states, and were even able to stop taking their antidepressants, often a state that lasted for many months after the healing trip. The fact that public money is now also flowing into research with psilocybin in Germany shows that psychedelic research is slowly edging from the fringes into the medical mainstream. Psychedelic substances have returned to where they once stood in the s and '60s — to the center of psychiatric, medical and psychological research. This could be seen in mid-September in Berlin, when the Insight conference took place, organized by the Mind Foundation. According to its website, the foundation advocates the 'evidence-based, safe and legal use of psychedelic experience in medicine and society. For four days, attendees discussed neurological processes, compared the effects of LSD, psilocybin and other drugs with diagrams, and presented the state of research in a wide variety of fields. Even an employee of the German drug approval authority, the federal authority for drugs and medical devices, was there. Experts are already enthusiastic. A growing number of companies are also keen. If they had their way, psilocybin, the ecstasy active ingredient MDMA and other substances would soon be used across the board to treat depression, addiction, and an array of other diseases. Angermayer has discussed his own psilocybin experiences in German media, including newspapers Handelsblatt and Wirtschaftswoche — and this summer he took his company public in New York. Compass Pathways is currently conducting a phase 2 trial with the drug involving more than patients at 22 locations in 10 countries, currently the largest psilocybin clinical trial in the world. The Berlin Registry of the Mind Foundation shows that the 'trip therapy boom' has allowed an entire industry to flourish. It lists about companies in the psychedelic industry, from A Whole New High, which offers psilocybin retreats in the Netherlands, to Wavepaths, a specialist for the right sound via headphones for an inward journey. Even Andrea Jungaberle is not entirely comfortable with the rapid development. Latest videos Latest audio. Latest audio Latest videos. In focus. Can 'magic mushrooms' help treat depression? Psilocybin on the stock market A growing number of companies are also keen. Skip next section Explore more Explore more Differences in personality: What psychiatrists can learn from mice to treat depression. Differences in personality: What psychiatrists can learn from mice to treat depression Scientists have developed a new way for measuring the personalities of animals. So why should we humans care? Because understanding personality traits is key for more individualized therapies in psychiatry. Coronavirus triggers mental health crisis in India. Coronavirus triggers mental health crisis in India India's coronavirus crisis has pushed millions into forced isolation and unemployment. Health experts warn that anxiety, depression and suicide are on the rise and that mental health could be the country's next crisis. UK sees depression rates nearly double amid lockdown. UK sees depression rates nearly double amid lockdown Nearly twice as many people were showing depression symptoms at the height of the UK lockdown compared to the pre-pandemic numbers. Young people were hit the hardest, official data shows. Related topics.